 |
||||||||||||||||||||||
|
 |
|
||||||||||||||||||||
 |
||||||||||||||||||||||
|
|
|||||||||||||||||||||
 |
 |
 |
 |
 |
 |
 |
||||||||||||||||
|
|
|||||||||||||||||||||
 |
||||||||||||||||||||||
Theragenomics Associates is a group of experts in theragenomics representing many years of experience in the field as it relates to drug efficacy and safety as well as to personalized and customized drug therapy. Theragenomics stands for the genomics of the huge variability in the response of single patients or groups of patients to drug therapy. Theragenomics comprises the newest knowledge from evidence based molecular medicine, including the pharmacogenetics (PGx) and toxicogenetics (TGx) of drugs in an attempt to better understand and predict the efficacy and the safety of selected therapies. Most importantly, theragenomic approaches help to identify genotype to phenotype (G to P) as well as phenotype to genotype (P to G) associations. For many drugs on the market today, such associations are well established and are based on valid DNA-based biomarkers and haplotypes of high positive (PPV) and high negative predictive value (NPV). Currently, such biomarkers include CYP2D6, CYP2C9, CYP2C19, UGTA1, TPMT, GST1, GSTM1, DIA4, SOD1, MPO, COMT, XRCC1, NQO1, SULT1A1, VKOR, NAT-2, FMO3, PON1, G6PD, EGFR, DPD, CCR5, LDL, Her-2/neu, PMT/RAR, C-KIT, HLA-B*1502, HLA-B*1302, among others.
Selected biomarkers may help to predict
in order to allow for the selection of therapies with the outmost efficacy and safety for single patients or groups of patients along with customized therapy recommendations.
Besides its application in clinical praxis, theragenomic knowledge may be applied in early drug candidate selection procedures and along the later stages of the critical path of drug development in preclinical and clinical development by characterization of the future behavior of drug candidates in targeted single patients or groups of patients. Theragenomic knowledge may similarly help to understand the response of single individuals or groups of individuals to agents beyond drugs, such as nutriceuticals and dietary supplements, herbal extracts, environmental and occupational agents and pollutants, agro- and petrochemicals and bulk & industrial chemicals, either unregulated or increasingly regulated through newly introduced legislation such as REACH.
Contact Theragenomics Associates Rieselbrunnackerweg 7 4203 Grellingen Switzerland E-mail: info@thasso.com Internet: http://www.thasso.com |
||||||||||||||||||||||
|
|
|||||||||||||||||||||
|
||||||||||||||||||||||
 |
||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|